HCA

Systematic screening of HCA Healthcare identifies an operationally efficient hospital network trading at a distinctive valuation disconnect. The company's P/E ratio of 13.81 sits well below broader healthcare sector multiples despite demonstrating robust EPS growth of 29.19% year-over-year and an 11.26% return on assets. This valuation compression occurs alongside a current price of $422.79, representing a 24% decline from the 52-week high of $556.52, potentially reflecting market concerns over the capital structure rather than operational deterioration.

Operational strengths evident in the fundamental data include:

• Exceptional gross margin of 85.0% indicating strong pricing power and cost management within the hospital systems
• Net margin of 8.89% combined with 6.71% revenue growth demonstrates sustained top-line expansion while maintaining profitability discipline
• Operating margin of 15.67% reflects effective facility-level execution across the portfolio

The model flags significant balance sheet concentration as a primary risk factor. The debt-to-equity ratio of 54.2 represents substantial financial leverage, while the book value per share of just $1.69 against a market price above $400 produces the extreme P/B ratio of 97.29. This capital structure amplifies both returns and risks—the 695.73% ROE reflects this leverage effect on equity returns. The current ratio of 0.97 indicates working capital constraints that merit ongoing monitoring.

Relative to peers THC, EHC, and ENSG, HCA's market capitalization of $93.8B positions it as the dominant hospital operator, with scale advantages reflected in its margin profile. The beta of 1.2 suggests moderate sensitivity to broader market movements while maintaining sector-specific healthcare demand characteristics.